---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-068819"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:25:30.413258+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Q3 net loss $7.7M; cash $107.1M; TARA-002 trials progressing

## Summary
- Net loss of $7.7M ($0.68/share) vs. $10.8M ($0.96) in Q3 2021; includes $1.4M stock-based compensation.
- Cash and investments $107.1M as of Sep 30, 2022; expected to fund operations into 2H2024.
- R&D expense $3.5M, down from $4.1M; G&A $4.5M, down from $6.7M year-over-year.
- Phase 1a dose escalation of TARA-002 in NMIBC ongoing; Phase 2 in LMs expected to start in 2023 after FDA feedback.
- IV Choline Chloride IFALD study ongoing; results to inform next steps.

## SEC filing metadata
- accession: 0001213900-22-068819
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/0001213900-22-068819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/ea167960-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-068819
- JSON: https://secwatch.observer/filing/0001213900-22-068819.json
- Plain text: https://secwatch.observer/filing/0001213900-22-068819.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $7.7 million, or $0.68 per share, EPS $0.68 per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: net loss of $7.7 million, or $0.68 per share
  - EPS: $0.68 per share
  - Result: reported results
  source text: Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/0001213900-22-068819-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.